Methyl Salicylate
Basic Information
| Item | Value |
|---|---|
| DrugBank ID | DB09543 |
| Evidence Level | L5 (Computational Prediction) |
| Number of Predicted Indications | 28 |
Predicted Indications (TxGNN)
The following are potential new indications predicted by the TxGNN model. Higher scores indicate higher predicted relevance.
| # | Indication | Source |
|---|---|---|
| 1 | gout | KG + DL |
| 2 | bronchitis | KG + DL |
| 3 | exostosis | KG + DL |
| 4 | congestive heart failure | KG + DL |
| 5 | osteoarthritis susceptibility | KG + DL |
| 6 | osteoarthritis | KG + DL |
| 7 | acute pulmonary heart disease | KG + DL |
| 8 | pseudoachondroplasia | KG + DL |
| 9 | rheumatoid arthritis | KG + DL |
| 10 | exostoses, multiple, | KG + DL |
| 11 | acromesomelic dysplasia, Hunter-Thompson type | KG + DL |
| 12 | disorder of O-xylosylglycan synthesis | KG + DL |
| 13 | brachyolmia | KG + DL |
| 14 | chronic kidney disease | KG + DL |
| 15 | arthropathy | KG + DL |
| 16 | brachyolmia-amelogenesis imperfecta syndrome | KG + DL |
| 17 | myosclerosis | KG + DL |
| 18 | epiglottitis | KG + DL |
| 19 | end stage renal failure | KG + DL |
| 20 | laryngotracheitis | KG + DL |
| 21 | chronic renal failure syndrome | KG + DL |
| 22 | Lesch-Nyhan syndrome | KG + DL |
| 23 | paratenonitis | KG + DL |
| 24 | calcific tendinitis | KG + DL |
| 25 | urinary tract infection (disease) | KG + DL |
| 26 | obsolete hyperuricemia (disease) | KG + DL |
| 27 | laryngitis | KG + DL |
| 28 | myositis | KG + DL |
Disclaimer
These predictions are for research purposes only and do not constitute medical advice. Clinical validation is required before any clinical application.